Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.42 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | HTR2C | P28335 | 2/20 | 0.39 |
| ▸ | HTR2B | P41595 | 2/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | BRD2 | P25440 | 1/20 | 0.37 |
| ▸ | NEK2 | P51955 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25476574 | 0.92 | CHRM2 (0.41) | CHRM2CHRM3GRIN1GRIN2ALTA4H | |
| SCHEMBL3436929 | 0.89 | CHRM2 (0.48) | CHRM2CHRM3GRIN1GRIN2ALTA4H | |
| SCHEMBL16190002 | 0.89 | GRIN1 (0.42) | CHRM2CHRM3GRIN1GRIN2ALTA4H | |
| SCHEMBL10186799 | 0.88 | GRIN1 (0.41) | CHRM2CHRM3GRIN1GRIN2ALTA4H | |
| SCHEMBL10186828 | 0.88 | GRIN1 (0.41) | CHRM2CHRM3GRIN1GRIN2ALTA4H | |
| SCHEMBL10186827 | 0.88 | GRIN1 (0.41) | CHRM2CHRM3GRIN1GRIN2ALTA4H | |
| SCHEMBL25738952 | 0.85 | GRIN1 (0.40) | CHRM2CHRM3GRIN1GRIN2ALTA4H | |
| SCHEMBL13460109 | 0.85 | GRIN1 (0.40) | CHRM2CHRM3GRIN1GRIN2ALTA4H | |
| SCHEMBL25959485 | 0.83 | GRIN1 (0.42) | CHRM2CHRM3GRIN1GRIN2ALTA4H | |
| SCHEMBL26456980 | 0.83 | GRIN1 (0.42) | CHRM2CHRM3GRIN1GRIN2ALTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220204507-A1 | NITROGEN-CONTAINING SPIRO DERIVATIVE AS RET INHIBITOR | GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS CO., LTD. BAIYUNSHAN PHARMACEUTICAL GENERAL FACTORY (CN) | 2022-06-30 | — | — | US | disclosed |
| EP-3950688-A1 | NITROGEN-CONTAINING SPIRO DERIVATIVE AS RET INHIBITOR | Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. Baiyunshan Pharmaceutical General Factory (CN) | 2022-02-09 | — | — | EP | disclosed |
| WO-2020200314-A1 | NITROGEN-CONTAINING SPIRO DERIVATIVE AS RET INHIBITOR | 南京明德新药研发有限公司 | 2020-10-08 | — | — | WO | disclosed |
| US-9718803-B2 | Unsaturated nitrogen heterocyclic compounds useful as PDE10 inhibitors | AMGEN INC. (US) | 2017-08-01 | — | — | US | disclosed |
| US-9662339-B2 | Benzodioxane inhibitors of leukotriene production for combination therapy | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-05-30 | — | — | US | disclosed |
| US-9662339-B2 | Benzodioxane inhibitors of leukotriene production for combination therapy | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-05-30 | — | — | US | disclosed |
| EP-2822941-B1 | BENZODIOXANES IN COMBINATION WITH STATINS FOR INHIBITING LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INT (DE) | 2017-05-10 | — | — | EP | disclosed |
| US-20160102075-A1 | UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | AMGEN INC. (US) | 2016-04-14 | — | — | US | disclosed |
| US-9133146-B2 | Benzodioxane inhibitors of leukotriene production | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-09-15 | — | — | US | disclosed |
| US-9133146-B2 | Benzodioxane inhibitors of leukotriene production | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-09-15 | — | — | US | disclosed |
| US-20130244996-A1 | BENZODIOXANE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-09-19 | — | — | US | disclosed |
| US-20130236468-A1 | BENZODIOXANE INHIBITORS OF LEUKOTRIENE PRODUCTION FOR COMBINATION THERAPY | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-09-12 | — | — | US | disclosed |
| US-20130236468-A1 | BENZODIOXANE INHIBITORS OF LEUKOTRIENE PRODUCTION FOR COMBINATION THERAPY | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-09-12 | — | — | US | disclosed |
| US-20130196973-A1 | BENZODIOXANE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-08-01 | — | — | US | disclosed |
| US-20130196973-A1 | BENZODIOXANE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-08-01 | — | — | US | disclosed |
| WO-2012125598-A1 | BENZODIOXANE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-09-20 | — | — | WO | disclosed |
| US-20120165331-A1 | Di/tri-aza-spiro-C9-C11alkanes | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2012-06-28 | — | — | US | disclosed |
| US-20110306587-A1 | UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | AMGEN INC. | 2011-12-15 | — | — | US | disclosed |
| WO-2011148962-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF | 大正製薬株式会社 (JP) | 2011-12-01 | — | — | WO | disclosed |
| WO-2011025690-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2011-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165331-A1 | Di/tri-aza-spiro-C9-C11alkanes | TACR2, TACR1, AGTR1 | CHRM2 204/4885CHRM3 1230/4885GRIN1 398/4885 |
| US-20130196973-A1 | BENZODIOXANE INHIBITORS OF LEUKOTRIENE PRODUCTION | LTA4H, LTB4R, LTC4S | CHRM2 883/4885CHRM3 1142/4885GRIN1 1245/4885 |
| US-20130244996-A1 | BENZODIOXANE INHIBITORS OF LEUKOTRIENE PRODUCTION | LTA4H, LTB4R, LTC4S | CHRM2 883/4885CHRM3 1142/4885GRIN1 1245/4885 |
| US-20220204507-A1 | NITROGEN-CONTAINING SPIRO DERIVATIVE AS RET INHIBITOR | RET, NPR1, NEK2 | CHRM2 4555/4885CHRM3 4349/4885GRIN1 684/4885 |
| US-20130236468-A1 | BENZODIOXANE INHIBITORS OF LEUKOTRIENE PRODUCTION FOR COMBINATION THERAPY | LTB4R, LTB4R2, LTC4S | CHRM2 514/4885CHRM3 533/4885GRIN1 1751/4885 |
| US-20160102075-A1 | UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | PDE10A, PDE2A, PDE3A | CHRM2 3055/4885CHRM3 3613/4885GRIN1 200/4885 |
| US-20110306587-A1 | UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | PDE10A, PDE2A, PDE3A | CHRM2 3055/4885CHRM3 3613/4885GRIN1 200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.